HomeNDC LookupIngredientsOlopatadine Hydrochloride › 62332-0501-05
OLOPATADINE HYDROCHLORIDE 1 mg/mL Solution/ Drops — NDC 62332-0501-05 package photo

OLOPATADINE HYDROCHLORIDE 1 mg/mL Solution/ Drops

by Alembic Pharmaceuticals Inc. · 1 BOTTLE, PLASTIC in 1 CARTON (62332-501-05) / 5 mL in 1 BOTTLE, PLASTIC
NDC 62332-0501-05
🏷️ FDA NDC (as labeled) 62332-501-05 billing pads the product segment with a zero
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 62332-501-05
Product NDC 62332-501
11-digit billing NDC 62332050105
NCPDP billing unit ML — per mL (volume)
RxCUI 1111339
UNII 2XG66W44KF
UPC 0362332501052
Application # ANDA209919
SPL Set ID 7b36e554-d68a-47e0-bf3c-f4cfdc3746b6
Established class (EPC) Histamine-1 Receptor Inhibitor
Mechanism of action Histamine H1 Receptor Antagonists
Physiologic effect Decreased Histamine Release
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2018-12-07
Route OPHTHALMIC
Dosage form SOLUTION/ DROPS
Substance OLOPATADINE HYDROCHLORIDE
GPI-14 86802065102020
GPI class Olopatadine HCl
GCN Seq No 030796
GCN 68321
HICL code 012815
Ingredient (HICL) Olopatadine Hcl
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6R
Therapeutic class — specific (HIC3) Eye Antihistamines
AHFS code 52:02.00.00
AHFS class Antiallergic Agents
FDB label name OLOPATADINE HCL 0.1% EYE DROPS
FDB brand name Olopatadine Hcl
Legend status F — Federal legend — prescription drug or device
Why two NDCs? The FDA registers this code as 62332-501-05 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 62332-0501-05. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Histamine-1 Receptor Inhibitor class.

Pharmacologic class Histamine-1 Receptor Inhibitor, Histamine-1 Receptor Antagonist, Mast Cell Stabilizer
Drug family (ATC) Antiallergic agents, excl. corticosteroids, Other antiallergics
How it works Histamine H1 Receptor Antagonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerAlembic Pharmaceuticals Inc.
Application holderALEMBIC PHARMACEUTICALS LTD
FDA applicationANDA209919 (ANDA)
Labeler code62332
First marketedDec 2018
Product typeHuman Prescription Drug
Portfolio491 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name OLOPATADINE HCL 0.1% EYE DROPS Ingredient Olopatadine Hcl
📖 What it is MedlinePlus · NLM

Prescription ophthalmic olopatadine (Pazeo) and nonprescription ophthalmic olopatadine (Pataday) are used to relieve itchy eyes caused by allergic reactions to pollen, ragweed, grass, animal hair, or pet dander. Olopatadine is in a class of medications called mast cell stabilizers. It works by preventing the release of substances that cause eye itching.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It does both, but with different products. The eye drops are for allergy-related itchy and red eyes. The nasal spray — brands like Patanase — is for seasonal allergic rhinitis, mea...
  • What exactly does olopatadine treat — is it just for eyes, or can it help my runny nose too?
  • You need to take your contacts out before you put the drops in. Wait at least 10 minutes after using the drops before you put them back in. Also, don't wear contacts at all if your...
  • Can I wear my contact lenses while using olopatadine eye drops?
📖 Read our full Olopatadine guide →

Supplement & herbal interactions

Some supplements/herbs that may interact with Olopatadine Hydrochloride — tap one for details:

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII F5UM2KM3W7
    Benzalkonium chloride is a chemical compound that works as a preservative and antimicrobial agent in medications. It prevents bacterial and fungal growth in liquid formulations to keep the product safe during storage and use.
  • UNII QTT17582CB
    A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
  • UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII GR686LBA74
    Sodium phosphate, dibasic is a salt derived from phosphoric acid. It acts as a buffer to help maintain the medicine's pH balance and may serve as a binder or filler in tablets and capsules.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

6 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $3.065 $15.32 / 5 ml
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Dec 2021 Jan 2022 $3.065 $2.649
▲ Up 16% over the last 2 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Eye Allergy Itch and Redness Relief 1 mg/mL 70000-0054-01 CARDINAL 1 bottle $1.221 Availability likely save 60%
Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 00536-1308-40 Rugby 1 bottle $1.223 Discontinued save 60%
Olopatadine Hydrochloride 1 mg/mL 00536-1445-40 RUGBY 1 bottle $1.268 Availability likely save 59%
olopatadine hydrochloride 1 mg/mL 16571-0882-05 Rising 5 ml $1.268 Availability likely save 59%
Olopatadine Hydrochloride Ophthalmic 1 mg/mL 43598-0765-07 Dr. 1 bottle $1.268 Availability likely save 59%
Olopatadine Hydrochloride 1 mg/mL 46122-0672-64 Amerisource 1 bottle $1.268 Availability likely save 59%
Leader Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 70000-0717-01 CARDINAL 1 bottle $1.268 Availability likely save 59%
Olopatadine 1 mg/mL 70069-0017-01 Somerset 1 bottle $1.268 Availability likely save 59%
Olopatadine Hcl 1 mg/mL 70512-0520-05 Sola 1 bottle $1.268 Availability likely save 59%
Eye Allergy Itch and Redness Relief 1 mg/mL 70677-1156-01 Strategic 1 bottle $1.268 Availability likely save 59%
Olopatadine Hydrochloride 1 mg/mL 70677-1280-01 Strategic 1 bottle $1.268 Availability likely save 59%
Pataday Twice A Day Relief 1 mg/mL 00065-4274-01 Alcon 1 bottle $2.482 Availability likely save 19%
Olopatadine Hydrochloride 1 mg/mLthis 62332-0501-05 Alembic 1 bottle $3.065 FDA listed
Olopatadine Hydrochloride 1 mg/mL 00363-0200-40 WALGREEN 1 bottle FDA listed
Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 00363-0867-01 WALGREEN 1 bottle FDA listed
Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 00363-7130-05 Walgreens 1 bottle FDA listed
Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 11673-0689-05 Target 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 11822-0064-01 RITE 1 bottle FDA listed
Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 11822-9976-05 Rite 1 bottle FDA listed
Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 24208-0966-01 Bausch 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 30142-0064-64 Kroger 1 bottle FDA listed
Eye Allergy Itch and Redness Relief Twice Daily Relief 1 mg/mL 43598-0826-07 Dr. 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 46122-0823-29 AmerisourceBergen 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 46708-0709-05 Alembic 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 50090-6341-00 A-S 1 bottle FDA listed
Olopatadine 1 mg/mL 50090-7959-00 A-S 1 bottle FDA listed
Olopatadine hydrochloride 1 mg/mL 51407-0663-05 Golden 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 51407-0938-05 Golden 1 bottle FDA listed
Olopatadine Hydrochloride Ophthalmic Solution Twice Daily 1 mg/mL 55910-0109-05 DOLGENCORP, 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 58602-0006-40 Aurohealth 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 58602-0009-40 Aurohealth 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 58602-0012-40 Aurohealth 1 bottle FDA listed
Olopatadine hydrochloride 1 mg/mL 60505-6221-00 Apotex 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 62332-0709-05 Alembic 1 bottle FDA listed
Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 63868-0822-05 Chain 1 bottle FDA listed
olopatadine hydrochloride ophthalmic 1 mg/mL 68083-0477-01 Gland 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 69168-0480-02 Allegiant 2 bottles FDA listed
CVS Eye Allergy Itch Relief Twice Daily 1 mg/mL 69842-0268-05 CVS 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 72036-0008-40 Harris 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 72476-0852-64 Retail 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 72657-0168-50 GLENMARK 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 76162-0020-40 TOPCO 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 79481-1000-01 Meijer 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 79903-0000-40 Wal-Mart 1 bottle FDA listed
Equate Olopatadine Hydrochloride Ophthalmic Solution 1 mg/mL 79903-0319-01 WAL-MART 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 82442-0966-01 TARGET 1 bottle FDA listed
Olopatadine Hydrochloride 1 mg/mL 85766-0111-05 Sportpharm 1 bottle FDA listed
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2018
On the market since
Dec 2018
📍
2026
Currently FDA-listed
8 years listed
🔓
·
Generic on the market
this product is a generic
This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
62332-0501-05 You're viewing this 1 BOTTLE, PLASTIC in 1 CARTON (62332-501-05) / 5 mL in 1 BOTTLE, PLASTIC 2018-12-07 Active

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 22 words

INDICATIONS AND USAGE Olopatadine hydrochloride ophthalmic solution USP, 0.1% is indicated for the treatment of the signs and symptoms of allergic conjunctivitis.

⏱️ Dosage and Administration 25 words

DOSAGE AND ADMINISTRATION The recommended dose is one drop in each affected eye two times per day at an interval of 6 to 8 hours.

Contraindications 29 words

CONTRAINDICATIONS Olopatadine hydrochloride ophthalmic solution USP, 0.1% is contraindicated in persons with a known hypersensitivity to olopatadine hydrochloride, USP or any components of olopatadine hydrochloride ophthalmic solution USP, 0.1%.

⚠️ Warnings 19 words

WARNINGS Olopatadine hydrochloride ophthalmic solution USP, 0.1% is for topical use only and not for injection or oral use.

🤒 Adverse Reactions 62 words

ADVERSE REACTIONS Headaches have been reported at an incidence of 7%. The following adverse experiences have been reported in less than 5% of patients: Asthenia, blurred vision, burning or stinging, cold syndrome, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, nausea, pharyngitis, pruritis, rhinitis, sinusitis, and taste perversion. Some of these events were similar to the underlying disease being studied.

🤰 Pregnancy 92 words

PREGNANCY Pregnancy Category C. Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 93,750 times the MROHD and rabbits treated at 400 mg/kg/day, or 62,500 times the MROHD, during organogenesis showed a decrease in live fetuses.

There are, however, no adequate and well controlled studies in pregnant women. Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.

🧒 Pediatric Use 18 words

PEDIATRIC USE Safety and effectiveness in pediatric patients below the age of 3 years have not been established.

🧓 Geriatric Use 17 words

GERIATRIC USE No overall differences in safety or effectiveness have been observed between elderly and younger patients.

🧬 Clinical Pharmacology ~1 min read

CLINICAL PHARMACOLOGY Olopatadine is an inhibitor of the release of histamine from the mast cell and a relatively selective histamine H 1 -antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors. Following topical ocular administration in man, olopatadine was shown to have low systemic exposure.

Two studies in normal volunteers (totaling 24 subjects) dosed bilaterally with olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks demonstrated plasma concentrations to be generally below the quantitation limit of the assay (<0.5 ng/mL). Samples in which olopatadine was quantifiable were typically found within 2 hours of dosing and ranged from 0.5 to 1.3 ng/mL. The half-life in plasma was approximately 3 hours, and elimination was predominantly through renal excretion.

Approximately 60-70% of the dose was recovered in the urine as parent drug. Two metabolites, the mono-desmethyl and the N-oxide, were detected at low concentrations in the urine. Results from an environmental study demonstrated that olopatadine hydrochloride ophthalmic solution USP, 0.1% was effective in the treatment of the signs and symptoms of allergic conjunctivitis when dosed twice daily for up to 6 weeks.

Results from conjunctival antigen challenge studies demonstrated that Olopatadine hydrochloride ophthalmic solution USP, 0.1% when subjects were challenged with antigen both initially and up to 8 hours after dosing, was significantly more effective than its vehicle in preventing ocular itching associated with allergic conjunctivitis.

📦 How Supplied / Storage and Handling 66 words

HOW SUPPLIED Olopatadine hydrochloride ophthalmic solution USP, 0.1% is supplied as follows: 5 mL in 5 mL screw neck white low density polyethylene bottle. 5 mL: NDC 62332-501-05 Storage : Store at 4° to 25°C (39° to 77°F) Rx Only Manufactured for: Alembic Pharmaceuticals, Inc. 750 Route 202, Bridgewater, NJ 08807 USA Manufactured by: Gland Pharma Limited D.P. Pally, Dundigal Post, Hyderabad-500 043, India Revised: 12/2018

📋 Description 119 words

DESCRIPTION Olopatadine hydrochloride ophthalmic solution USP, 0.1% is a sterile ophthalmic solution containing olopatadine, a relatively selective H 1 -receptor antagonist and inhibitor of histamine release from the mast cell for topical administration to the eyes. Olopatadine hydrochloride, USP is a white, crystalline, water-soluble powder with a molecular weight of 373.88. The chemical structure is presented below: Chemical Name: 11-[(Z)-3-(Dimethylamino)propylidene]-6-11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride Each mL of olopatadine hydrochloride ophthalmic solution USP, 0.1 % contains: Active : 1.11 mg olopatadine hydrochloride, USP equivalent to 1 mg olopatadine.

Preservative: Benzalkonium chloride 0.01%. Inactives: Dibasic sodium phosphate; Sodium chloride; Hydrochloric acid/Sodium hydroxide (adjust pH); and Water for Injection. It has a pH of approximately 7 and an osmolality of approximately 300 mOsm/kg. chemical-structure

💬 Information for Patients 122 words

INFORMATION FOR PATIENTS To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use. Patients should be advised not to wear a contact lens if their eye is red.

Olopatadine hydrochloride ophthalmic solution USP, 0.1% should not be used to treat contact lens related irritation. The preservative in Olopatadine hydrochloride ophthalmic solution USP, 0.1%, benzalkonium chloride, may be absorbed by soft contact lenses. Patients who wear soft contact lenses and whose eyes are not red should be instructed to wait at least ten minutes after instilling Olopatadine hydrochloride ophthalmic solution USP, 0.1% before they insert their contact lenses.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.